# ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

> **NCT02387762** · PHASE2 · COMPLETED · sponsor: **Acerta Pharma BV** · enrollment: 31 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** acalabrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02387762
- **Lead sponsor:** Acerta Pharma BV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-05
- **Final completion:** 2016-06
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387762, "ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT02387762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*